The present invention is related to a conjugate comprising a structure of general formula (I) [TM1] - [AD1] - [LM] - [AD2] - [TM2] (I),whereinTM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target,AD1 is a first adapter moiety or is absent,LM is a linker moiety or is absent,AD2 is a second adapter moiety or is absent, andTM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second targetwherein the first targeting moiety and/or the second targeting moiety is a compound of formula (II):whereinR1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethylAA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acidR2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3C8)cycloalkylmethyl, halogen, nitro and trifluoromethylALK is (C2-C5)alkylideneR3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the following formula (III)whereinALK is (C2-C5)alkylideneR6 is selected from the group consisting of hydrogen and (C1-C4)alkyl andR7 is a bondor a pharmacologically acceptable salt, solvate or hydrate thereof.
